Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR446422
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SAR446422 is a bispecific antibody developed by Sanofi for the treatment of inflammatory diseases. It is engineered to simultaneously target and modulate two critical T-cell costimulatory pathways: CD28 and OX40 (also known as CD134 or TNFRSF4). By dual-targeting these receptors, the molecule aims to suppress aberrant T-cell activation and restore immune homeostasis in autoimmune and inflammatory contexts. SAR446422 is currently undergoing Phase 1 clinical evaluation, including studies in healthy participants and patients with atopic dermatitis, to assess its safety, tolerability, and preliminary activity.
02
Targets
Beyond the preview
Go deeper on SAR446422.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR446422.